Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck

被引:2265
|
作者
Cooper, JS [1 ]
Pajak, TF
Forastiere, AA
Jacobs, J
Campbell, BH
Saxman, SB
Kish, JA
Kim, HE
Cmelak, AJ
Rotman, M
Machtay, M
Ensley, JF
Chao, KSC
Schultz, CJ
Lee, N
Fu, KK
机构
[1] NYU Med Ctr, New York, NY 10016 USA
[2] Radiat Therapy Oncol Grp Headquarters, Philadelphia, PA USA
[3] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA
[4] Wayne State Univ, Sch Med, Detroit, MI USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] NCI, Bethesda, MD 20892 USA
[7] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[8] Vanderbilt Canc Ctr, Nashville, TN USA
[9] SUNY Hlth Ctr Brooklyn, Brooklyn, NY USA
[10] Univ Penn Hlth Syst, Philadelphia, PA USA
[11] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
[12] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 350卷 / 19期
关键词
D O I
10.1056/NEJMoa032646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Despite the use of resection and postoperative radiotherapy, high-risk squamous-cell carcinoma of the head and neck frequently recurs in the original tumor bed. We tested the hypothesis that concurrent postoperative administration of cisplatin and radiotherapy would improve the rate of local and regional control. METHODS Between September 9, 1995, and April 28, 2000, 459 patients were enrolled. After undergoing total resection of all visible and palpable disease, 231 patients were randomly assigned to receive radiotherapy alone ( 60 to 66 Gy in 30 to 33 fractions over a period of 6 to 6.6 weeks) and 228 patients to receive the identical treatment plus concurrent cisplatin (100 mg per square meter of body-surface area intravenously on days 1, 22, and 43). RESULTS After a median follow-up of 45.9 months, the rate of local and regional control was significantly higher in the combined-therapy group than in the group given radiotherapy alone ( hazard ratio for local or regional recurrence, 0.61; 95 percent confidence interval, 0.41 to 0.91; P = 0.01). The estimated two-year rate of local and regional control was 82 percent in the combined-therapy group, as compared with 72 percent in the radiotherapy group. Disease-free survival was significantly longer in the combined-therapy group than in the radiotherapy group ( hazard ratio for disease or death, 0.78; 95 percent confidence interval, 0.61 to 0.99; P= 0.04), but overall survival was not ( hazard ratio for death, 0.84; 95 percent confidence interval, 0.65 to 1.09; P= 0.19). The incidence of acute adverse effects of grade 3 or greater was 34 percent in the radiotherapy group and 77 percent in the combined-therapy group ( P< 0.001). Four patients who received combined therapy died as a direct result of the treatment. CONCLUSIONS Among high-risk patients with resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantly improve the rates of local and regional control and disease-free survival. However, the combined treatment is associated with a substantial increase in adverse effects.
引用
收藏
页码:1937 / 1944
页数:8
相关论文
共 50 条
  • [1] Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck
    Tanvetyanon, Tawee
    Padhya, Tapan
    McCaffrey, Judith
    Kish, Julie A.
    Deconti, Ronald C.
    Trotti, Andy
    Rao, Nikhil G.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (06): : 840 - 845
  • [2] Postoperative radiotherapy for high-risk head and neck squamous cell carcinoma
    Hamamoto, Y.
    Tsuruoka, S.
    Takata, N.
    Ishikawa, H.
    Nagasaki, K.
    Mochizuki, T.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 141 : S55 - S55
  • [3] ADJUVANT CHEMOTHERAPY FOR HIGH-RISK SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    JOHNSON, JT
    MYERS, EN
    SCHRAMM, VL
    MAYERNIK, DG
    NOLAN, TA
    SIGLER, BA
    WAGNER, RL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) : 456 - 458
  • [4] Postoperative concurrent chemo-radiotherapy with a modified cisplatin schedule in high-risk squamous-cell carcinoma of the head and neck (HNSCC)
    Schena, M.
    Rampino, M.
    Passeri, L.
    Barone, C.
    Grillo, R.
    Migliaccio, F.
    Pecorari, G.
    Cavalot, A.
    Garzino-Demo, R.
    Ciuffreda, L.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 338 - 338
  • [5] A PROSPECTIVE TRIAL OF ACCELERATED RADIOTHERAPY IN THE POSTOPERATIVE TREATMENT OF HIGH-RISK SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    TROTTI, A
    KLOTCH, D
    ENDICOTT, J
    RIDLEY, M
    GREENBERG, H
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (01): : 13 - 21
  • [6] RADIOTHERAPY FOR POSTOPERATIVE RECURRENT SQUAMOUS-CELL CARCINOMA IN HEAD AND NECK
    DEUTSCH, M
    LEEN, R
    PARSONS, JA
    MERCADO, R
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1973, 98 (05) : 316 - 318
  • [7] CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY WITH CISPLATIN IN INOPERABLE SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - AN RTOG STUDY
    ALSARRAF, M
    PAJAK, TF
    MARCIAL, VA
    MOWRY, P
    COOPER, JS
    STETZ, J
    ENSLEY, JF
    VELEZGARCIA, E
    [J]. CANCER, 1987, 59 (02) : 259 - 265
  • [9] Postoperative radiotherapy with simultaneous chemotherapy in high-risk squamous cell carcinoma of the head and neck: a novel standard that opens new questions
    Jordi Giralt
    Jacques Bernier
    [J]. Clinical and Translational Oncology, 2005, 7 (5) : 181 - 182
  • [10] HIGH-RISK HEAD AND NECK CANCERS TREATED WITH POSTOPERATIVE CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY: IMPACT ON OUTCOMES
    Benavente, S.
    Ramos, M.
    Giralt, J.
    Urdambidelus, A.
    Hermosilla, E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S255 - S256